Seattle Genetics to Present at Upcoming Investor Conferences

BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (NASDAQ: SGEN) announced today that management will present at the following upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section.

Cowen and Company 36th Annual Health Care ConferenceTuesday, March 8, 11:20 a.m. Eastern Time, Boston

Barclays Global Healthcare ConferenceWednesday, March 16, 11:15 a.m. Eastern Time, Miami

About Seattle Genetics

Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. The company’s lead product, ADCETRIS® (brentuximab vedotin), is a CD30-targeted ADC that, in collaboration with Takeda Pharmaceutical Company Limited, is commercially available in 60 countries, including the U.S., Canada, Japan and members of the European Union. Additionally, ADCETRIS is being evaluated broadly in more than 70 ongoing clinical trials in CD30-expressing malignancies. Seattle Genetics is also advancing vadastuximab talirine (SGN-CD33A; 33A), an ADC that is expected to advance into a phase 3 trial for acute myeloid leukemia in 2016. Beyond ADCETRIS and 33A, the company is developing a robust pipeline of clinical-stage programs, including denintuzumab mafodotin (SGN-CD19A; 19A), SGN-LIV1A, ASG-15ME, ASG-22ME (enfortumab vedotin), SGN-CD70A and SEA-CD40. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including AbbVie, Agensys (an affiliate of Astellas), Bayer, Genentech, GlaxoSmithKline and Pfizer. More information can be found at www.seattlegenetics.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160301005411/en/

Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
[email protected]

Source: Seattle Genetics, Inc.

You May Also Be Interested In

• New Memecoin News: MemeToro’s Automated BNB Chain Memecoin Deployment Explained
• Best AI Crypto Coins August 2026: MemeToro, Chainlink and Virtuals Protocol in Focus
• Crypto News Today: MemeToro Presale Gains Attention as JPMorgan Boosts IBIT and ETHA Holdings by Double Digits